Rice-based oral antibody fragment prophylaxis and therapy against rotavirus infection

Daisuke Tokuhara,1,2 Beatriz Álvarez,3 Mio Mejima,1 Tomoko Hiroiwa,1 Yuko Takahashi,1 Shiko Kurokawa,1 Masaharu Kuroda,4 Masaaki Oyama,5 Hiroko Kozuka-Hata,5 Tomonori Nochi,1 Hiroshi Sagara,5 Farah Aladin,6 Harold Marcotte,3 Leon G.J. Frenken,7 Miren Iturriza-Gómara,8 Hiroshi Kiyono,1,9 Lennart Hammarström,3 and Yoshikazu Yuki1,9

1Division of Mucosal Immunology, Department of Microbiology and Immunology, The Institute of Medical Science, University of Tokyo, Tokyo, Japan. 2Department of Pediatrics, Osaka City University Graduate School of Medicine, Osaka, Japan. 3Division of Clinical Immunology, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden. 4Crop Development Division, NARO Agriculture Research Center, Nigata, Japan. 5Medical Proteomics Laboratory, The Institute of Medical Science, University of Tokyo, Tokyo, Japan. 6Enteric Virus Unit, Virus Reference Department, Health Protection Agency, London, United Kingdom. 7Unilever Research and Development Vlaardingen BV, Vlaardingen, Netherlands. 8Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom. 9International Research and Development Center for Mucosal Vaccine, The Institute of Medical Science, University of Tokyo, Tokyo, Japan.

Rotavirus-induced diarrhea is a life-threatening disease in immunocompromised individuals and in children in developing countries. We have developed a system for prophylaxis and therapy against rotavirus disease using transgenic rice expressing the neutralizing variable domain of a rotavirus-specific llama heavy-chain antibody fragment (MucoRice-ARP1). MucoRice-ARP1 was produced at high levels in rice seeds using an overexpression system and RNAi technology to suppress the production of major rice endogenous storage proteins. Orally administered MucoRice-ARP1 markedly decreased the viral load in immunocompetent and immunodeficient mice. The antibody retained in vitro neutralizing activity after long-term storage (>1 yr) and boiling and conferred protection in mice even after heat treatment at 94°C for 30 minutes. High-yield, watersoluble, and purification-free MucoRice-ARP1 thus forms the basis for orally administered prophylaxis and therapy against rotavirus infections.

Introduction

Rotavirus is the leading cause of diarrhea in infants and young children worldwide, causing more than 114 million episodes of diarrhea annually in children under the age of 5 (1–4), 80% of which occur in developing countries (4). More than 600,000 children die annually from rotavirus (RV) infection, and although most RV-related deaths occur in low-income countries, in developed countries, thousands of children under 5 years of age are hospitalized every year, including approximately 50,000–80,000 in Japan and 60,000 in the US (2, 3), causing a huge financial burden (2, 5). Currently, there are 2 licensed RV vaccines (Rotarix and RotaTeq) that have been reported to be highly effective (>85%) in reducing severe RV-induced diarrhea in developed countries (6–8). More recent clinical trials in developing countries in Africa and Asia (9–11) have also demonstrated a potential impact of these vaccines, but with a markedly lower efficacy, ranging from 39.3% (RotaTeq in Sub-Saharan Africa) to 61.2% (Rotarix in Malawi and South Africa) (9, 10). Both vaccines have proven to be safe in clinical trials and post-marketing studies, but presently, they are licensed for use only within a very narrow age window (≥6 weeks and ≤26 weeks of age) to avoid the risk of intussusception.

Vaccines are often associated with poor efficacy in immunocompromised individuals (12–14). Such individuals may even acquire infections derived from the use of live vaccines. Cases of chronic diarrhea induced by the attenuated RotaTeq vaccine have indeed been recently reported (12–14), and the current RV vaccines are therefore not recommended for use in immunodeficient infants.

The lag time between vaccine administration and induction of an immune response, as well as poor efficacy in immunocompromised individuals, can be critical in highly endemic regions and outbreak situations, such as those occurring in hospital settings (15–18). Furthermore, severely immunocompromised individuals do not mount protective immunity when infected with RV and thus suffer chronic infection (19–22), which can subsequently lead to extraintestinal spread with severe clinical consequences (19–21). There is still a need for alternative strategies that can be used in situations where the available vaccines are not indicated and/or to complement vaccination strategies in situations where efficacy of vaccination alone may not be sufficient.

Passive immunotherapy is, at present, the only available intervention that can provide immediate protection. It may thus represent the prophylaxis of choice in highly endemic areas where vaccine responses may be poor or in selected groups of patients such as hospitalized children, immunocompromised individuals, and older infants and children in whom vaccination is contraindicated. It has been previously shown that oral administration of polyclonal antibodies from various sources can be used successfully both as

Conflict of interest: ARP1 has been patented by Unilever and was provided under a material transfer agreement for research relating to the application of the technology to food products. Leon G.J. Frenken owns shares in Unilever. Miren Iturriza-Gómara receives research support provided by GlaxoSmithKline and Sanofi Pasteur MSD.

Note regarding evaluation of this manuscript: Manuscripts authored by scientists associated with Duke University, The University of North Carolina at Chapel Hill, Duke-NUS, and the Sanford-Burnham Medical Research Institute are handled not by members of the editorial board but rather by the science editors, who consult with selected external editors and reviewers.

Citation for this article: J Clin Invest. 2013;123(9):3829–3838. doi:10.1172/JCI70266.
prophylaxis and as therapy in children with RV-induced diarrhea (23, 24). However, the production and purification of the antibodies is costly, making it necessary to find alternative approaches.

The variable domain of llama heavy chain antibodies (VHH) consists of a single domain and constitutes the smallest naturally occurring antigen-binding domain known to date (25). In addition to its high binding capacity, VHH has several attractive features, such as resistance to pepsin, acid environment, and heat (26, 27). Furthermore, because of its small size and simple form, it is easy to produce VHH as a recombinant protein with an intact protease domain (P-mUBi, ubiquitin promoter; LB, T-DNA left border; RB, T-DNA right border). (B) Production of MucoRice-ARP1. SDS-PAGE showed predominant expression of the transgenic protein with a molecular weight of approximately 12 kDa (arrowhead). Original rice proteins (arrows; 22- to 23-kDa and 34- to 37-kDa subunits of glutelin and 13-kDa prolamin) in nontransformed WT rice were markedly suppressed in MucoRice-ARP1. Western blotting revealed that a transgenic protein of 12 kDa was specifically detected using the anti-ARP1 antibody. ARP1 E. coli, ARP1 purified from E. coli. (C) Solubility of MucoRice-ARP1. MucoRice-ARP1 (PBS), extracts of MucoRice-ARP1 in PBS; MucoRice-ARP1 (urea), extracts of MucoRice-ARP1 in 8 M urea. (D) Immunohistochemistry showed that ARP1 had accumulated throughout the whole MucoRice-ARP1 seed, whereas it was not detected in a WT rice seed. Scale bars: 1 mm. (E) Immune electron microscopy showed that ARP1 is observed as black spots (left and middle panels). ARP1 is predominantly localized in the PB-II and the interspace between the PB-I and PB-II (left and middle panels). ARP1 is also slightly found at the surface of PB-I (left panel and lower middle panel). ARP1 is not detected in a WT rice seed used as a negative control (right panel). Scale bars: 1 μm.

**Results**

Development of rice-based water soluble ARP1 (MucoRice-ARP1) with a high expression level. Using a binary vector (pZH2Bik45G1B) (35), described in Figure 1A, a codon-optimized ARP1 gene combined with a RNAi suppression cassette was transfected into rice plants (Nippon-Bare) using Agrobacterium tumefaciens-mediated transformation. As shown in Figure 1B, the expression of the prolamin (13 kDa) and glutelin (22–23 kDa and 34–37 kDa) was suppressed and the 12 kDa ARP1 protein was predominantly expressed in the transgenic rice (MucoRice-ARP1). When accumulation of the ARP1 protein in the MucoRice-ARP1 seed was examined by SDS-PAGE and Western blot, using a rabbit anti-ARP1 polyclonal antibody, 1 band (12 kDa) was detected under denaturing conditions (Figure 1B). ARP1 was released from the MucoRice-ARP1 rice powder after PBS addition at room temperature (rice water) as shown in Figure 1C. Using densitometric analysis, with purified yeast-derived ARP1 as a standard, the yield of soluble ARP1 (which is 95% of the total yield) was found to reach an average of 170 μg per seed, representing 11.9% of the total seed protein (0.85% of seed weight). In contrast, transgenic rice, without RNAi suppression of prolamin and glutelin, yielded a low amount of ARP1 (on average 14 μg/seed) (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI70266DS1).

Localization of ARP1 protein in a MucoRice-ARP1 seed. Immunohistochemistry staining showed that MucoRice-ARP1 is expressed throughout the entire seed (Figure 1D). Storage proteins of WT rice seeds generally accumulate into 2 different types of protein bodies (PB), PB-I and PB-II, which contain prolamin and glutelin as their major components, respectively (36). PB-I is resistant to digestive enzyme whereas PB-II is easily digested in the gut (37). When the sections were examined by immune electron microscopy, ARP1 was predominantly localized in PB-II and the cytoplasm between PB-I and PB-II (Figure 1E).

Mass spectrometric analyses of MucoRice-ARP1. Using Q-STAR and Orbitrap mass spectrometry, we determined the full sequence of the 123 amino acids of ARP1 and the N-terminal sequence (serine-arginine) derived from the restriction enzyme site (XbaI) necessary for introduction of the ARP1 encoding gene into the binary vector (Supplemental Tables 1 and 2).

Heat stability and long-term room temperature stability of MucoRice-ARP1. MucoRice-ARP1 showed a binding to rhesus RV (RRV) particles similar to that of yeast-derived ARP1 (BAC BV, Naarden, the Netherlands) (Supplemental Figure 2). In order to determine the heat stability of MucoRice-ARP1, ARP1 (from rice and yeast) and bovine hyperimmune colostrum (HBC) (38) were boiled for 10, 20, and 30 minutes. After 30 minutes of boiling, a loss in the binding capacity to RV using ELISA of between 33% and 57% was observed in the ARP1 samples. It is worth noting that rice water containing MucoRice-ARP1 (protein solution from MucoRice-ARP1 powder in PBS) showed a higher heat resistance (33% loss in the binding capacity after 30 minutes of boiling) than the purified ARP1 samples from MucoRice-ARP1 (57% loss) and yeast (46% loss). In contrast, the HBC sample completely lost its binding activity already after 10 minutes of boiling (Supplemental Figure 3).

Furthermore, MucoRice-ARP1, stored at room temperature (>1 year), had a neutralizing activity against RV in vitro equal to...
that of freshly harvested MucoRice-ARP1 when applied as rice water (Supplemental Figure 4).

**MucoRice-ARP1 neutralizes human RV strains of different serotypes in vivo.** Neutralization assays, preventing infection in MA104 cells, were carried out to determine whether MucoRice-ARP1 was able to detect human RV strains of different serotypes (Figure 2). MucoRice-ARP1 containing rice water neutralized the human RV strains Wa G1P[8], ST-3 G4P[6], 69M G8P[10], F45 G9P[8] and Va70 G4P[8] in a dose-dependent manner. A reduction of more than 60% in the infectivity of the RV strains F45, 69M, and Va70 was observed in vitro using the same dose of MucoRice-ARP1 and purified yeast-derived ARP1 (1.25 μg ml⁻¹). For neutralization of the RV strains ST-3 and Wa, 4 times the amount of rice water of MucoRice-ARP1 (10 μg ml⁻¹) was needed as compared with purified yeast-derived ARP1 (2.5 μg ml⁻¹) (Figure 2).

**MucoRice-ARP1 reduced diarrhea in a mouse pup model of RV infection.** All 4-day-old mice infected with RVV and given PBS or WT rice developed diarrhea (Figure 3, A-C) whereas none of the noninfected control mice (fed PBS or WT rice) did (Figure 3, A-C). When MucoRice-ARP1 (containing 8.5 μg of ARP1) was prophylactically given to neonatal mice, the percentage of animals with diarrhea on day 2 after RVV inoculation was significantly lower (P = 0.007) than in mice receiving PBS or WT rice (Figure 3A). In addition, disease severity in mice treated with MucoRice-ARP1 was significantly lower (P = 0.022 and P = 0.041) than in mice given PBS or WT rice. Heat treated MucoRice-ARP1 (for 10 minutes or 30 minutes at 94°C) used prophylactically against RVV-induced diarrhea also significantly (P = 0.035) reduced the percentage of animals with diarrhea on day 2 in comparison with mice receiving PBS or WT rice. In addition, disease severity in mice treated with heat-treated MucoRice-ARP1 was significantly lower (P = 0.041) than in mice given PBS or WT rice. No significant difference was observed between heat-treated and non–heat treated MucoRice-ARP1 in their ability to reduce the percentage of mice with diarrhea and disease severity (Figure 3A).

As shown in Figure 3B, long-term (>1 year) stored MucoRice-ARP1 (8.5 μg ARP1) applied prophylactically significantly reduced the incidence of diarrhea and disease severity (P = 0.011 and P = 0.008, respectively on day 2) compared with that of mice receiving PBS and was as effective as freshly harvested MucoRice-ARP1 (P = 0.297 and P = 0.267, respectively on day 2).

When MucoRice-ARP1 was given therapeutically, 9 hours after RVV inoculation, the percentage of mice with the virus-induced diarrhea and disease severity was also significantly lower (P = 0.007 and P = 0.041, respectively on day 2) than in the control mice receiving PBS or WT rice (Figure 3C).

**Histopathological changes and virus loads in the small intestine of neonatal murine pups.** No lesions were seen in any of the control mice receiving PBS and sacrificed on day 3 (Figure 4A). In the RVV-infected neonatal mice that received WT rice water solution or PBS, all of the examined mice showed typical histological signs of RV infection, with accumulation of large vacuoles in the enterocytes lining the surface of the villous tips in the ileum (Figure 4, B and D). Some vacuoles were also detected in the duodenum and the jejunum (data not shown). RVV-infected mice treated prophylactically with the MucoRice-ARP1 preparation showed no pathological changes (Figure 4C). When VP7 mRNA–specific RT-PCR was performed, the level of virus load tended to correlate with the histopathological changes. Thus, the virus load in the intestines of RVV-inoculated mice that received MucoRice-ARP1 was significantly reduced compared with that of mice given PBS (n = 6, P = 0.002) or WT rice (P < 0.01) (n = 6, P = 0.002) (Figure 4E).

**Stability of MucoRice-ARP1 in the neonatal mice gut.** Intragastrically administered MucoRice-ARP1 containing rice water (8.5 μg of soluble ARP1) was detected in the small intestine of the mice (4 days after birth) for at least 6 hours (Supplemental Figure 5). In some mice (40%, n = 5), MucoRice-ARP1 could be detected even 9 hours after intragastric administration.

**MucoRice-ARP1 reduces the viral shedding in SCID mice.** Following challenge with RRV, watery diarrhea was observed in all SCID neonatal pups. MucoRice-ARP1 (containing 8.5 μg of ARP1), given therapeutically to SCID pups 9 hours after RVV inoculation, significantly reduced the percentage of mice with diarrhea (P = 0.022) and disease severity (P = 0.038) compared with SCID pups given PBS or WT rice (Supplemental Figure 6).

Adult SCID mice did not develop overt diarrhea. However, the mice suffered a chronic infection lasting more than 6 weeks, as recognized by viral shedding in feces (Figure 5). Oral administration of 200 mg of MucoRice-ARP1 powder (containing 1.7 mg of soluble ARP1) twice daily for 7 days markedly reduced the number of viral VP7 RNA copies in feces on day 3 and day 9 (n = 6, P = 0.002 and 0.003) compared with that in mice given PBS or WT rice. No difference was, however, observed after the cessation of MucoRice-ARP1 administration (day 14) (Figure 5). No reduction in viral shedding was observed in RVV-inoculated SCID adult mice treated with WT rice powder compared with mice receiving PBS. These data indicate that MucoRice-ARP1 can transiently, but effectively, decrease the shedding of RV even in immunocompromised adult mice.
Discussion

Although we have previously developed an oral rice-based vaccine expressing botulinum neurotoxin type A against botulism and CTB for cholera/enterotoxicogenic E. coli (ETEC) (32, 33), expression of a cytokine or antibody such as human IL-10 or single-chain Fv (scFv) from an M cell–specific monoclonal antibody in rice resulted in insoluble proteins. Thus, we could not apply these proteins orally (data not shown). The present study markedly extends the potential of rice plants into an antibody production system. Using the MucoRice technology, we successfully produced the variable domain of a RV-specific llama-heavy chain antibody and showed that oral administration of MucoRice-ARP1 afforded protection in mice. Unique features of this product, including water solubility, high expression level, heat stability, and long-term stability upon storage at room temperature, make MucoRice-ARP1 an attractive ready-to-use, oral, anti-RV product that can easily be distributed without the need for a cold chain.

Figure 3
MucoRice-ARP1–mediated protection in a mouse pup model of RV infection. (A) Prophylactic administration of MucoRice-ARP1 containing rice water (8.5 μg of ARP1) given to 4-day-old neonatal mouse litters 9 hours prior to RRV inoculation and subsequently given twice daily for 4 consecutive days. Results are shown as percentage of mice with diarrhea and mean diarrhea severity. (B) Prophylactic administration of long-term stored MucoRice-ARP1 containing rice water given 9 hours prior to RRV inoculation and subsequently given twice daily for 4 consecutive days. (C) Therapeutic administration of MucoRice-ARP1 (8.5 μg of ARP1) given 9 hours after RRV inoculation and subsequently given twice daily for 4 consecutive days. Statistical significance among groups was calculated using the Kruskal-Wallis test followed by the Mann-Whitney U test.

The Journal of Clinical Investigation  http://www.jci.org  Volume 123  Number 9  September 2013  3833
extremely high yield of soluble antibodies (8.5 g soluble ARP1 kg\(^{-1}\) of VHH) described previously (40–43), the MucoRice system achieved an order to allow expansion of space for ARP1 in the rice seeds (33). In

As suppression of internal storage protein production may enhance accumulation of foreign proteins (44), we introduced RNAi to the ARP1 production system and developed a T-DNA expression system by co-introduction of antisense genes specific for the 13-kDa prolamin and glutelin storage proteins to minimize their expression in order to allow expansion of space for ARP1 in the rice seeds (33). In comparison with those plant-based antibodies (scFv, IgG, Fab, and VHH) described previously (40–43), the MucoRice system achieved an extremely high yield of soluble antibodies (8.5 g soluble ARP1 kg\(^{-1}\) of total weight or 11.9% of total protein) in rice seeds. Most important, MucoRice-ARP1 is highly water soluble (Figure 1C) due to the localization of the ARP1 antibody fragment in the PB-II and cytoplasm fractions, which are the soluble components of rice (Figure 1E).

A second important aspect of the plant-based antibody system is that, in contrast with previous systems, there is no need for purification. As MucoRice-ARP1 originates from edible rice seeds, the obtained rice powder can be directly used as an ingredient for use

A third important aspect is that cold-chain transport and storage are unnecessary, as RV antibodies are primarily needed in developing
countries. Antibody-producing tobacco leaves need storage under -20 degrees, and antibody-producing tomatoes need a temperature below 4 degrees. In contrast, antibody-producing cereals such as rice and wheat as well as pea seeds can be stored at room temperature (39). In this study, we demonstrated that MucoRice-ARP1 was stable at room temperature for more than 1 year. Furthermore, in a boiling experiment, extracts from MucoRice-ARP1 demonstrated a higher heat resistance than the purified ARP1 from MucoRice-ARP1 and from yeast-based ARP1, suggesting that the presence of rice proteins in the sample contributes to an increased stability of ARP1. The high stability of MucoRice-ARP1 confers an economic advantage over products that require a cold-chain for distribution and storage. The cost effectiveness of MucoRice-ARP1, added to the fact that rice is one of the most important types of staple food, may contribute to making this product accepted and affordable and thus especially suitable for populations in developing countries where the burden of RV-induced diarrhea is high.

RV-induced diarrhea in humans is caused by RVs belonging to group A. A large number of serotypes have been isolated from infected individuals, although the most common serotypes worldwide are G1P[8], G2P[4], G4P[8], and G9P[8] (45). It has recently been shown that yeast produced ARP1 can neutralize a broad range of virus serotypes in vitro (M37 G1[P6], Wa G1[P8], R+G1[P8], DS-1 G2[P4], P G3[P8], ST-3 G4[P4], Va70 G4[P8], 69M G8[P10], WI-61 G9[P8], F45 G9[P8]) (31). Moreover, it could also bind the recently emerged G8, G10, and G12 strains (31). In this study, we showed that ARP1 produced in rice (MucoRice-ARP1) neutralizes RV strains in a range similar to that of the yeast produced ARP1. Thus, it should be possible to use rice-based ARP1 treatment regardless of geographical differences in strain diversity.

The broad reactivity and neutralizing capacity of ARP1 indicates that it recognizes crossreactive epitopes. The outer layer proteins of RV, VP7 and VP4, both contain neutralizing epitopes, although these tend to be serotype specific (31). The middle layer protein, VP6, is the most abundant and immunodominant viral protein and contains the group and subgroup determining epitopes (31). Iturriza-Gomara et al. recently identified the epitope recognized by ARP1 and showed that it binds to polymeric VP6 (31), thus explaining its broad neutralization capacity. With regard to the role of anti-VP6 antibodies against RV-induced diarrhea, crossreactive anti-RV VP6 antibodies appear to be unable to neutralize infection by immune exclusion both in vitro and in vivo. However, some anti-VP6 secretory IgA bind to RV double
The neutralizing capacity associated with the recognition of the constituent proteins of the RV inner, middle and outer layers and of the marked impact of the protein-protein interactions among layer VP4 can be altered by interactions with different VP7 proteins and/or entry of the virus particle, as previously suggested (31, 50). Proteins of the RV particle, VP7 and/or VP4, preventing attachment specific VHH could block a conformational change in the outer layer neutralize infection is not yet understood, it is possible that the VP6- neutralization assays and in an in vivo mouse pup model, which suggests that these antibodies are likely to neutralize RV by immune exclusion (31, 50–53). Although the mechanism by which the llama antibodies neutralize infection is not yet understood, it is possible that the VP6-specific VH4 could block a conformational change in the outer layer proteins of the RV particle, VP7 and/or VP4, preventing attachment and/or entry of the virus particle, as previously suggested (31, 50). This is supported by existing evidence that the phenotype of the outer layer VP4 can be altered by interactions with different VP7 proteins and of the marked impact of the protein-protein interactions among the constituent proteins of the RV inner, middle and outer layers (54). The neutralizing capacity associated with the recognition of crossreactive epitopes within VP6 of these antibodies may also relate to their small size, as bivalent VH4 antibodies showed a much reduced neutralizing activity compared with the monovalent VH4, suggesting that these may have no or limited access to the exposed VP6 of an infectious triple-layered RV particle (50).

A recent clinical trial in Bangladesh proved that yeast-derived ARP1 was effective in reducing the severity of the disease in RV-infected children with no adverse events considered to be related to ARP1 treatment (S. A. Sarker, M. Jäkel, S. Sultana, N. H. Alam, P. K. Bardhan, M. A. Salam, W. Theis, L. Hammarström, L. G. Frenken, unpublished observations), and, as there are no differences in the efficacy between the yeast-derived ARP1 and MucoRice-ARP1 in vitro, the latter has a potential to be equally effective in a clinical setting. With regard to the safety of the rice seed component, we have used a rice-based cholera vaccine in 5 cynomolgus macaques and did not observe any adverse events (55, 56). Rice seed itself is an edible plant; thus, taken together with the present results, we consider MucoRice-ARP1 to be safe and to be able to provide effective protection against RV-induced diarrhea. One remaining problem is the dose translation between mouse and human based on the body surface area normalization between animals and human adults (57, 58). The dose for neonatal (17 μg/d) or adult (SCID) mice (3.4 mg/d) translates as 0.7 mg of ARP1/kg/d (82 mg of MucoRice-ARP1 powder per kg/d) and 20.7 mg/kg/d of ARP1 (107 mg/d of MucoRice-ARP1 powder per mg/d), respectively, in 6–24-month-old children. In the recent Bangladesh study, in which 6–24-month-old children with RV diarrhea were treated, 5–10 mg of ARP1/kg 3 times per day was used, equivalent to a daily ARP1 dose of 15–30 mg/kg/d. Thus, the dose of rice-produced ARP1 we used for neonatal and SCID mice is lower, or at least equivalent, to the dose given to children in the Bangladesh study.

Therapeutic proteins produced using recombinant DNA technologies are generally complex, heterogeneous, and subject to a variety of enzymatic or chemical modifications during expression (59). Since efficacy, clearance, and immunogenicity can be highly dependent on the protein sequence and specific posttranslational modifications, it is important to characterize their structure by determining the sequence of the recombinant protein and amino acid modifications that may affect the safety and activity of therapeutic protein products using analytical tools such as mass spectrometry (60). However, to date there is no report showing the complete amino acid sequence of plant-derived therapeutics, including vaccines, antibodies, or enzymes. Using mass spectrometry, we elucidated the full amino acid sequence of plant-derived therapeutics, confirming that it does not contain any amino acid modifications. The complete amino acid sequence of plant-derived therapeutics, including vaccines, antibodies, or enzymes. Using mass spectrometry, we elucidated the full amino acid sequence of plant-derived therapeutics, confirming that it does not contain any amino acid modifications. The present study is thus the first, to our knowledge, to include this information for the safety and efficacy of the product.

In conclusion, we have developed a high-yield, purification-free, cold-chain-free, and heat stable, rice-based antibody fragment containing product for oral administration that provides protection against RV of different serotypes in vitro and reduction of virus shedding and disease in both immunocompetent and immunodeficient mice. MucoRice-ARP1 offers what we believe is a novel approach to the prevention and treatment of RV-induced diarrhea in both develop-
oped and developing countries and may provide an alternative to vaccination in individuals in whom current vaccines are contraindicated. It could also complement current vaccination programs by targeting different age groups and situations in which rapid protection or control of spread of infection is required. This technology can also be extended to the production of antibody fragments against other enteric pathogens such as norovirus, and may also be applicable to intestinal diseases beyond infections.

**Methods**

DNA constructs and transformation of rice plants. ARP1 was selected from a library of VHH fragments generated from llamas immunized with RRV (strain MMU18006, PSB[3], G3) (61), as previously described (29). Briefly, a phage display library was constructed from B lymphocyte cDNA encoding VH3s and selected by biopanning on RRV at a low pH (2.3). ARP1 was previously referred to as 2B10 (29) or VH11 (30). The gene encoding ARP1 was synthesized with an optimized codon usage for plants and inserted into a binary T-DNA vector (pZH2B/3S/SN). This vector contains a cassette for overexpression of ARP1 and a combination cassette for RNAi suppression of production of the major rice endogenous storage proteins, prolamin (13 kDa) and glutelin (Figure 1A and ref. 35). The plasmid was subsequently given twice daily for 4 consecutive days. In order to examine the heat stability, samples with 100 ng ml–1 were intragastrically administered to the pups 9 hours prior to RRV inoculation and subsequently given twice daily for 4 consecutive days. In the control groups, PBS or MucoRice-ARP1 treated at 94°C for 10 and 30 minutes or stored at room temperature over negative pressure in the animal facility on a 12-hour light/12-hour dark cycle. Food and deionized water were autoclaved and provided ad libitum.

To determine the level of protection against RRV infection conferred by MucoRice-ARP1 in immunocompetent mice (BALB/c), 4-day-old pups were infected orally using 2 × 104 ffu trypsin-activated RRV (n = 6 to 10 per group). Rice water derived from the supernatant of a mixture of MucoRice-ARP1 powder and PBS, containing a total of 8.5 μg of ARP1, was intragastrically administered to the pups 9 hours prior to RRV inoculation and subsequently given twice daily for 4 consecutive days. In order to examine the heat stability and long-term stability at room temperature, MucoRice-ARP1 heat-treated at 94°C for 10 and 30 minutes or stored at room temperature over 1 year was intragastrically administered to the pups prior to RRV inoculation and subsequently given twice daily for 4 consecutive days. In order to examine the therapeutically effective of MucoRice-ARP1, MucoRice-ARP1 was intragastrically given to the pups 9 hours after RRV inoculation and subsequently given twice daily for 4 consecutive days. In the control groups, PBS or MucoRice-ARP1 was intragastrically administered twice daily for 4 consecutive days without RRV inoculation. The pups were examined daily for evidence of RV-induced diarrhea by gentle abdominal palpation. Diarrhea was recorded and scored blindly from 1 to 4 based on stool color, amount, and consistency as described previously, with a minor modification (65). Normal feces or absence of feces were given a score of 1. Exceptionally loose feces were given a score of 2. Loose yellow-green feces were given a score of 3. Watery feces were given a score of 4. A score of 2 or greater was considered diarrhea, as described previously (65). The percentage of mice with diarrhea for each group was calculated by dividing the number of diarrheic samples by the total number of mice scored for diarrhea each day. The diarrhea severity was determined by dividing the sum of all scores by the number of total number of mice scored for diarrhea each day. Finally, we calculated percentage of mice with diarrhea on a daily basis in each group based on accumulated data.
after repeated experiments and compared the percentage of diarrhea and the mean diarrhea severity on day 2 after RRV inoculation among groups using the Kruskal-Wallis test followed by the Mann-Whitney test. Samples of small intestine were collected 3 days after infection for histopathological analysis and viral RNA quantification by real-time PCR against VP7 RNA.

Evaluation of histopathology. To evaluate histopathology, small intestinal samples were collected at 3 days after RRV inoculation (n = 3 for each group). Samples from duodenum, jejunum, and ileum were fixed in 4% paraformaldehyde for 12 hours. Subsequently, the samples were transferred to graded ethanol for dehydration, embedded in paraffin wax, and sectioned at 4 μm using a microtome. Sections were stained with H&E and visualized under light microscope. Duodenal, jejunal, or ileal villi were examined for presence of enterocyte injury, inflammation, and vacuolization by a person blinded to the treatment given to the mice.

Quantification of viral RNA. Total RNA was isolated from small intestines of neonatal pups, using TRIzol reagent (Life Technologies), and treated with RNase-free DNase (QIAGEN) following the manufacture’s protocol. To evaluate viral shedding in the chronic RRV infection SCID mouse model, fecal specimens were prepared as 10% suspensions with PBS, and total RNA was isolated using TRIzol following the manufacturer’s protocol. VP7 mRNA or viral genomic RNA was amplified at 58°C in the presence of 600 nmol l–1 primers, 300 nmol l–1 probe, and 5 nmol l–1 Mn to generate a 121-bp–long amplicon. The sense primer (VP7 forward, 5′-CCAAGGGAAAATGTGACGATTTC-3′; nt 791-815), the antisense primer (VP7 reverse, 5′-TGCCACATTCTTTTC-CAATTAAA-3′; nt 891-912), and the probe (5′-6FAMTAACGGCTATCCACAACACAGCACCATMRAA-3′; nt 843-867) were designed on the basis of the VP7 gene sequence of RRV (GenBank AF295303). Reverse transcription reactions were carried out in a final volume of 20 μl using Superscript III Reverse Transcriptase (Invitrogen) following the manufacturer’s protocol. Each RT reaction sample was analyzed by the Light-Cycler 480 System II (Roche Applied Science) following the manufacturer’s protocol. A standard curve was generated using a plasmid that contained a RRV VP7 gene, and the lowest level of detection of the PCR was 10 viral RNA copies. The presence of less than 10 copies of VP7 RNA per weight (mg) was defined as clearance of infection. The ratio of VP7 gene copy number to the weight of the stool sample (mg) or to the weight of the small intestine segment (mg) was compared among the groups.

In vivo assays in SCID mice. The efficacy of MucoRice-ARP1 against chronic RRV infection was determined in SCID mice. Pregnant C.B-17 SCID/SCID mice were purchased from Nihon Clea Inc. Four-day-old pups were infected orally with 2 × 10^7 ffu RRV. All of the mice developed diarrhea and chronic infection. The litters were weaned by removing each mouse from the dam at 21 days of age. After inoculation, all mice were confirmed to have low serum immunoglobulin levels by ELISA and examined for pathogen surveillance, but no specific pathogen, including murine norovirus, was found at 5 weeks of age. When mice were 6 weeks old (i.e., 6 weeks after RRV infection), 200 mg of MucoRice-ARP1 powder (containing 1.7 mg of ARP1) or nontransformed WT rice powder was intragastrically administered twice daily for 7 consecutive days. Mice were examined on days –1, 1, 3, 9, and 14 for diarrhea and viral shedding. Diarrhea score, percentage of mice with diarrhea, and disease severity were measured as described above. Viral shedding was measured by VP7-specific real-time PCR using fecal samples. In order to examine the therapeutic effects of MucoRice-ARP1 in SCID mouse pups, MucoRice-ARP1 was intra-gastrically given to the pups 9 hours after RRV inoculation and subsequently given twice daily for 4 consecutive days. Diarrhea score, percentage of animals with diarrhea, and disease severity were measured as described above.

Statistics. Individual data for the percentage of mice with diarrhea, the disease severity scores, and differences in the intestinal virus load as assessed by real-time PCR were analyzed using the Kruskal-Wallis test followed by the Mann-Whitney test. P < 0.05 was considered statistically significant.

Study approval. All mouse experiments were approved by the local ethics committee of the Institute of Medical Science at the University of Tokyo.

Acknowledgments

This work was supported by grants from the Programs of Special Coordination Funds for Promoting Science and Technology, the Grant-in-Aid for Scientific Research on Priority Areas, and the Grant-in-Aid for Scientific Research (A and S) of the Ministry of Education, Culture, Sports, Science, and Technology of Japan (to H. Kiyono); the Ministry of Health, Labor and Welfare of Japan (to Y. Yuki and H. Kiyono); Core Research of Evolutional Science Technology (CREST) of the Japan Science and Technology Agency (JST) (to H. Kiyono); the New Energy and Industrial Technology Development Organization (NEDO) (to Y. Yuki and H. Kiyono); the Young Researcher Overseas Visits Program for Vitalizing Brain Circulation of the Japan Society for the Promotion of Science (JSPS) (to H. Kiyono and Y. Yuki); the Global Center of Excellence Program Center of Education and Research for Advanced Genome-Based Medicine – For Personalized Medicine and the Control of Worldwide Infectious Diseases (to H. Kiyono); a research fellowship of the Japan Society for the Promotion of Science (to T. Nochi); Adaptive and Seamless Technology Transfer Program Through Target-Driven R&D (A-Step) (to Y. Yuki); the Japan Foundation for Pediatric Research (to D. Tokuhara); a Houjinkai fellowship award of the Department of Pediatrics at Osaka City University Graduate School of Medicine (to D. Tokuhara); the Association for Preventive Medicine of Japan (to D. Tokuhara); and the European Union–funded project LACTO-BODY (202162). We are grateful to H. Hatai, Y. Chen, and A. Cyubachi for technical support. We thank T. Masumura and K. Tanaka of the Kyoto Prefectural Institute of Agricultural Biotechnology for support. We also thank J. Kusiwawa of the Institute of Medical Science, the University of Tokyo, and K. Fujihashi of the University of Alabama at Birmingham for support. We would like to thank N. Pant for technical advice regarding the in vivo neutralization assays and the animal model of rotavirus infection.

Received for publication April 2, 2013, and accepted in revised form June 13, 2013.

Address correspondence to: Yoshikazu Yuki, Department of Mucosal Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, 108-8639, Japan. Phone: 81.3.5449.5274; Fax: 81.3.5449.5411; E-mail: yukiy@ims.u-tokyo.ac.jp.


The Journal of Clinical Investigation http://www.jci.org Volume 123 Number 9 September 2013 3837